Overexpression of Cyclooxygenase-2 in Rat Oral Cancers and Prevention of Oral Carcinogenesis in Rats by Selective and Nonselective COX Inhibitors

被引:36
作者
McCormick, David L. [1 ]
Phillips, Jonathan M. [1 ]
Horn, Thomas L. [1 ]
Johnson, William D. [1 ]
Steele, Vernon E. [2 ]
Lubet, Ronald A. [2 ]
机构
[1] IIT, Res Inst, Life Sci Grp, Chicago, IL 60616 USA
[2] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MAMMARY CARCINOGENESIS; UNITED-STATES; ROFECOXIB; CELECOXIB; ASPIRIN; CHEMOPREVENTION; NAPROXEN; TOBACCO; EVENTS;
D O I
10.1158/1940-6207.CAPR-09-0151
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide (NQO) show substantial overexpression of cyclooxygenase-2 (COX-2) when compared with adjacent phenotypically normal oral tissues. By contrast, neither 5-lipoxygenase (LOX) nor 12-LOX is overexpressed in rat oral cancers. Two chemoprevention studies were done to test the resulting hypothesis that COX-2 is a useful target for oral cancer chemoprevention in the rat. In both studies, male F344 rats received drinking water exposure to NQO (20 ppm) for 10 weeks, followed by administration of chemopreventive agents from week 10 until study termination at week 26. In the first study, groups of rats were fed basal diet (control), or basal diet supplemented with the selective COX-2 inhibitor celecoxib (500 or 1,500 mg/kg diet), the nonselective COX inhibitor piroxicam (50 or 150 mg/kg diet), or the 5-LOX inhibitor zileuton (2,000 mg/kg diet). In the second study, rats were fed basal diet (control) or basal diet supplemented with nitric oxide-naproxen (180 or 90 mg/kg diet), a nonselective COX inhibitor that shows reduced gastrointestinal toxicity. When compared with dietary controls, celecoxib decreased oral cancer incidence, cancer invasion score, and cancer-related mortality. Piroxicam decreased cancer-related mortality and cancer invasion score, whereas nitric oxide-naproxen decreased oral cancer incidence and cancer invasion score. By contrast, zileuton showed no chemopreventive activity by any parameter assessed. These data show that both selective and nonselective inhibitors of COX-2 can prevent NQO-induced oral carcinogenesis in rats. The chemopreventive activity of COX inhibitors may be linked to overexpression of their enzymatic target in incipient oral neoplasms. Cancer Prev Res; 3(1); 73-81. (c) 2010 AACR.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 34 条
[1]  
[Anonymous], 2009, CANC FACTS FIG 2009
[2]   Celecoxib for the prevention of sporadic colorectal adenomas [J].
Bertagnolli, Monica M. ;
Eagle, Craig J. ;
Zauber, Ann G. ;
Redston, Mark ;
Solomon, Scott D. ;
Kim, KyungMann ;
Tang, Jie ;
Rosenstein, Rebecca B. ;
Wittes, Janet ;
Corle, Donald ;
Hess, Timothy M. ;
Woloj, G. Mabel ;
Boisserie, Frederic ;
Anderson, William F. ;
Viner, Jaye L. ;
Bagheri, Donya ;
Burn, John ;
Chung, Daniel C. ;
Dewar, Thomas ;
Foley, T. Raymond ;
Hoffman, Neville ;
Macrae, Finlay ;
Pruitt, Ronald E. ;
Saltzman, John R. ;
Salzberg, Bruce ;
Sylwestrowicz, Thomas ;
Gordon, Gary B. ;
Hawk, Ernest T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) :873-884
[3]   Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial [J].
Bertagnolli, Monica M. ;
Eagle, Craig J. ;
Zauber, Ann G. ;
Redston, Mark ;
Breazna, Aurora ;
Kim, KyungMann ;
Tang, Jie ;
Rosenstein, Rebecca B. ;
Umar, Asad ;
Bagheri, Donya ;
Collins, Neal T. ;
Burn, John ;
Chung, Daniel C. ;
Dewar, Thomas ;
Foley, T. Raymond ;
Hoffman, Neville ;
Macrae, Finlay ;
Pruitt, Ronald E. ;
Saltzman, John R. ;
Salzberg, Bruce ;
Sylwestrowicz, Thomas ;
Hawk, Ernest T. .
CANCER PREVENTION RESEARCH, 2009, 2 (04) :310-321
[4]   Smokeless tobacco and cancer [J].
Boffetta, Paolo ;
Hecht, Stephen ;
Gray, Nigel ;
Gupta, Prakash ;
Straif, Kurt .
LANCET ONCOLOGY, 2008, 9 (07) :667-675
[5]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[6]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[7]   Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial [J].
Clouser, Mary C. ;
Roe, Denise J. ;
Foote, Janet A. ;
Harris, Robin B. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (04) :276-283
[8]   Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials [J].
Cole, Bernard F. ;
Logan, Richard F. ;
Halabi, Susan ;
Benamouzig, Robert ;
Sandler, Robert S. ;
Grainge, Matthew J. ;
Chaussade, Stanislas ;
Baron, John A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (04) :256-266
[9]   Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis [J].
Corley, DA ;
Kerlikowske, K ;
Verma, R ;
Buffler, P .
GASTROENTEROLOGY, 2003, 124 (01) :47-56
[10]   The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the US Preventive Services Task Force [J].
Dube, Catherine ;
Rostom, Alaa ;
Lewin, Gabriela ;
Tsertsvadze, Alexander ;
Barrowman, Nicholas ;
Code, Catherine ;
Sampson, Margaret ;
Moher, David .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (05) :365-375